Direct Acting Anti-Viral's In Chronic HCV Patients

Getz Pharma511 enrolled

Overview

The objective of the study is to determine the safety of DAA's among chronic HCV patients. The outcomes of the study are; To determine the frequency of adverse events while receiving DAAs with or without RBV and/or Pegylated Interferon To calculate the percentage of patients with severity of medical event as per Karch and Lasagna classification To determine the percentage of patient having serious adverse event as per ICH Classification

The cross sectional survey data will be collected on a pre-defined questionnaire from Gastroenterologist and Hepatologist. The questionnaire will provide us information on demographics, relevant patient history, concomitant medication, ongoing treatment plan recommended for chronic HCV and adverse event details. The questions related to Pharmacovigilance and safety assessment includes the International Nonproprietary Names (INN) unless it is prescribed brand of Getz Pharma. All adverse events associated with the prescribed treatment will be recorded. Data on outcome assessment will be based on action taken due to AE and other reported details. Seriousness of adverse event will also be recorded as per the ICH classification and severity of medical event will be assessed as per Karch and Lasagna classification. All the information will be recorded by the healthcare professionals on the questionnaire during direct interaction with the patients. Patients' written authorization to use and/or disclose the patient's personal and/or health data will be obtained. However, patient data secrecy will follow ICH GCP requirements.

Study Type

OBSERVATIONAL

Enrollment

511

Conditions

Safety Issues

Interventions

SofosbuvirDRUG

the occurrence of AEs (AE) and their severity among chronic HCV patients has assessed in patinets receiving different combinations of DAAs in Pakistani Population

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Written informed consent 2. Male or Female patient 3. Age of patient ≥18 years 4. Patients already diagnosed with HCV and on DAAs therapy. Exclusion Criteria: 1. Written informed consent 2. Male or Female patient 3. Age of patient ≥18 years 4. Patients already diagnosed with HCV and on DAAs therapy.

Locations (1)

Liver Center Faisalabad

Faisalabad, Punjab Province, Pakistan

Outcomes

Primary Outcomes

Frequency of adverse events while receiving DAAs with or without RBV and/or Pegylated Interferon

Time frame: 12 months

Secondary Outcomes

Percentage of patients reported severity of medical event as per Karch and Lasagna classification

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.